{
    "clinical_study": {
        "@rank": "142937", 
        "arm_group": [
            {
                "arm_group_label": "EPI-743 400mg", 
                "arm_group_type": "Active Comparator", 
                "description": "EPI-743 at a dose of 400 mg three times daily"
            }, 
            {
                "arm_group_label": "EPI-743 200mg", 
                "arm_group_type": "Active Comparator", 
                "description": "EPI-743 at a dose of 200 mg three times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of EPI-743 in patients with Parkinson's\n      disease."
        }, 
        "brief_title": "A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of Parkinson's disease\n\n          2. Age 40 - 75\n\n          3. Ambulatory with or without assistance\n\n          4. Hoehn and Yahr Scale score of 1 - 3\n\n          5. Patient able to consent and comply with protocol requirements\n\n          6. Abstention from use of Coenzyme Q10, vitamin E, Azilect and Idebenone two weeks prior\n             to enrollment and during course of treatment with EPI-743\n\n        Exclusion Criteria:\n\n          1. Allergy to EPI-743 or sesame oil\n\n          2. Allergy to vitamin E\n\n          3. Clinical history of bleeding or abnormal baseline PT/PTT\n\n          4. Diagnosis of any other neurologic disease\n\n          5. Malignancy within past two years\n\n          6. Pregnant or plans to become pregnant\n\n          7. Concomitant ophthalmologic disease\n\n          8. History of stroke\n\n          9. History of brain surgery\n\n         10. Inability to undergo MRI scan or MRS\n\n         11. Hepatic insufficiency with LFTs greater than two times upper limit of normal\n\n         12. Renal insufficiency requiring dialysis\n\n         13. End stage cardiac failure\n\n         14. Fat malabsorption syndromes precluding drug absorption\n\n         15. Use of anticoagulant medications, azilect"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923584", 
            "org_study_id": "EPIPD"
        }, 
        "intervention": [
            {
                "arm_group_label": "EPI-743 400mg", 
                "intervention_name": "EPI-743 400mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPI-743 200mg", 
                "intervention_name": "EPI-743 200mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "cward2@health.usf.edu", 
                "last_name": "Christopher Ward", 
                "phone": "813-974-5909"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "University of South Florida"
            }, 
            "investigator": {
                "last_name": "Theresa Zesiewicz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "cward2@health.usf.edu", 
            "last_name": "Christopher Ward", 
            "phone": "813-974-5909"
        }, 
        "overall_contact_backup": {
            "email": "kbarber@health.usf.edu", 
            "last_name": "Kelly Sullivan, PhD", 
            "phone": "813-974-5909"
        }, 
        "overall_official": {
            "affiliation": "University of South Florida", 
            "last_name": "Theresa Zesiewicz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "electroretinogram and color vision", 
            "measure": "Visual function", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "UPDRS subscales", 
                "measure": "Neurologic function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "UPDRS subscales", 
                "measure": "Motor function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Magnetic Resonance spectroscopy (MRS)", 
                "measure": "Brain metabolites", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Montreal Cognitive Assessment (MoCA)", 
                "measure": "Cognitive function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Beck Depression Inventory (BDI)", 
                "measure": "Mood", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Blood biomarker levels", 
                "measure": "Disease biomarkers", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "University of South Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "Edison Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of South Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}